Key Takeaways
- Baxdrostat is an experimental once-a-day pill that significantly reduces blood pressure in patients with resistant hypertension.
- It works as an aldosterone synthase inhibitor, blocking the production of aldosterone, which contributes to high blood pressure.
- In a Phase III trial with 800 patients, baxdrostat reduced systolic blood pressure by an average of 15.7 mmHg compared to 5.8 mmHg for the placebo group.
- A reduction of nearly 10 mmHg in systolic blood pressure is linked to lower risks of serious health issues such as heart attack and stroke.
- The drug is considered safe, though some patients experienced elevated potassium levels, indicating it may become a preferred treatment option for hypertension.
An experimental once-a-day pill named baxdrostat has been proven to significantly reduce blood pressure in individuals whose pressure remains dangerously high even when treated with various other medications. These findings were part of an international Phase III trial directed by Professor Bryan Williams.
How Baxdrostat Works
This innovative drug, reported in The New England Journal of Medicine, is categorized as an aldosterone synthase inhibitor. It works by directly blocking the production of aldosterone, a hormone. Elevated levels of aldosterone are a primary contributor to resistant hypertension, as it leads the body to hold onto excess salt and water.
Trial Details and Results
The BaxHTN Phase III trial was a double-blind study that involved around 800 patients suffering from controlled or resistant hypertension. After 12 weeks, participants who received a daily dose of 2 mg of baxdrostat along with their existing treatment experienced an average decrease in systolic blood pressure of 15.7 mmHg. In contrast, those on a placebo only saw an average reduction of 5.8 mmHg. This results in a statistically important, placebo-adjusted decrease of 9.8 mmHg.
Implications for Heart Health
Achieving a nearly 10 mmHg reduction in systolic blood pressure is thrilling, as this extent of decrease is associated with a markedly lower risk of heart attack, stroke, heart failure, and kidney disease, according to Professor Williams.
The research team determined the drug to be safe, although about 3% of those taking the medication experienced elevated potassium levels, in comparison to just 0.4% of the placebo group. This indicates that the drug has a strong potential to become a preferred option for individuals dealing with hypertension.
Source: Link